App	lication No.	Applicant(s)
Notice of Allowability	042,052	RAITANO ET AL.
	miner	Art Unit
	id J. Blanchard	1643
The MAILING DATE of this communication appears of All claims being allowable, PROSECUTION ON THE MERITS IS (OR Inherewith (or previously mailed), a Notice of Allowance (PTOL-85) or ot NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313 and	REMAINS) CLOSED in this ap her appropriate communicatior <b>S.</b> This application is subject to	will be mailed in due course. THIS
1. This communication is responsive to <u>02 May 2006</u> .		
2. X The allowed claim(s) is/are 88, 90-91, 94-98 (renumbered as cla	<u>aims 1-8)</u> .	
a) ☐ Acknowledgment is made of a claim for foreign priority under 3 a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have been 2. ☐ Certified copies of the priority documents have been 3. ☐ Copies of the certified copies of the priority documents have been 3. ☐ Copies of the certified copies of the priority documents have been 3. ☐ Copies of the certified copies of the priority documents have been 3. ☐ Copies of the certified copies of the priority documents have been deposited to provide the priority documents have been deposited by the priority documents have been deposited attached Examiner's comment regarding REQUIREMENT FOREST.	n received. In received in Application No ents have been received in this is communication to file a reply of this application.  Note the attached EXAMINER ason(s) why the oath or declar submitted. Patent Drawing Review ( PTC mendment / Comment or in the c)) should be written on the draw eader according to 37 CFR 1.121	rational stage application from the complying with the requirements  R'S AMENDMENT or NOTICE OF ration is deficient.  D-948) attached  Office action of rings in the front (not the back) of 1(d).  must be submitted. Note the
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Summar Paper No./Mail D 7. Examiner's Amen	oate

Application/Control Number: 09/942,052

Art Unit: 1643

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with James J. Mullen III, Ph.D. on 23 May 2006.

This Application has been amended as follows:

In claim 90 (renumbered as claim 2), the term "claim 89" has been deleted and replaced with the term "claim 88".

In claim 96 (renumbered as claim 6) the term "taxol," has been deleted.

In the specification (filed 12/6/05) at page 12, line 14 the term "taxol" has been deleted and replaced with the term "TAXOL™".

## STATEMENT OF REASONS FOR ALLOWANCE

2. The following is an examiner's statement of reasons for allowance:

The present application is in condition for allowance in view of the amendments to claim 88, which recite that the claimed monoclonal antibody is conjugated to a diagnostic agent or a cytotoxic agent. While Williams et al (Molecular Microbiology, 27(1):171-186, 1998, previously cited on PTO-892 mailed 9/17/04) teach the OIP5 polypeptide, which is identical to the polypeptide of SEQ ID NO:728, Williams et al state

Application/Control Number: 09/942,052

Art Unit: 1643

ý.

that the function of the OIP5 polypeptide is unknown (see pg. 174, 2<sup>nd</sup> column). Thus, there is no requisite motivation to target a diagnostic or cytotoxic agent to the OIP5 polypeptide using an antibody specific for SEQ ID NO:728 (i.e., the OIP5 polypeptide). It is also noted that applicant's previously submitted declaration under 37 CFR 1.132 by Dr. Karen Jane Meyrick Morrison on 10/20/2005, demonstrates that the claimed polypeptide (SEQ ID NO:728) is expressed in prostate and lung cancer tissue.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Blanchard whose telephone number is (571) 272-0827. The examiner can normally be reached at Monday through Friday from 8:00 AM to 6:00 PM, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, can be reached at (571) 272-0832. The official fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Application/Control Number: 09/942,052

Art Unit: 1643

For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully, David J. Blanchard 571-272-0827

> SHEELA HUFF PRIMARY EXAMINER